瑞戈非尼与他莫昔芬治疗铂敏感复发性卵巢癌生化复发:REGOVAR II期随机试验
REGOVAR研究纳入68例铂敏感卵巢癌伴单纯CA-125升高、无RECIST或症状进展的患者,随机接受瑞戈非尼或他莫昔芬治疗。中位随访32个月,两组无进展生存无差异(P=0.72),瑞戈非尼组3/4级不良事件发生率90.9%,高于他莫昔芬组54.3%。
要点
- 瑞戈非尼在他莫昔芬治疗铂敏感卵巢癌生化复发时无疗效优势
- 瑞戈非尼3/4级不良事件发生率90.9%,高于他莫昔芬的54.3%
- 手足综合征在瑞戈非尼组发生率为36.4%
核心结论
- 瑞戈非尼毒性谱较他莫昔芬更差,且在该人群中无疗效优势。
研究设计与样本
- GINECO开展的随机II期试验(REGOVAR),计划随机116例,实际随机68例铂敏感卵巢癌伴单纯CA-125升高患者。
- 瑞戈非尼口服160或120 mg每日,3周服药/1周停药;他莫昔芬40 mg每日,直至疾病进展或不可耐受毒性。
- 主要终点为RECIST 1.1进展或任何原因死亡评估的无进展生存。
主要发现
- 中位随访32个月,瑞戈非尼组与他莫昔芬组无进展生存无差异(P=0.72)。
- 他莫昔芬组中位无进展生存5.6个月(90%CI:3.84-7.52),瑞戈非尼组4.6个月(90%CI:3.65-7.33)。
- 总生存、最佳缓解、CA-125缓解及至下次治疗时间两组均无差异。
- 瑞戈非尼组3/4级事件发生率90.9%,他莫昔芬组54.3%,最常见为皮肤、消化及生物学事件。
- 瑞戈非尼组手足综合征发生率为36.4%。
关键数值与推荐
- 铂敏感卵巢癌生化复发定义为CA-125升高而无放射学(RECIST标准)或症状性进展证据。
- 患者中位年龄67岁(范围30-87),92.6%原发部位为卵巢,89.7%为浆液性,83.6%为高级别,69.6%初诊FIGO III期。
- 79.4%患者在一线铂类治疗后入组。
临床怎么用
- 对于铂敏感卵巢癌单纯CA-125升高、无临床或RECIST进展者,他莫昔芬较瑞戈非尼更具安全性优势。
- 瑞戈非尼在该人群不推荐优于他莫昔芬使用,需权衡毒性。
局限性
- 实际随机68例,低于计划的116例。
- 为II期试验,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of regorafenib versus tamoxifen in platinum-sensitive ovarian cancer biological recurrence, defined by CA-125 increase without radiological (RECIST criteria) or symptomatic evidence of progression. PATIENTS AND METHODS: 116 patients with platinum-sensitive ovarian cancer presenting an isolated increase of CA-125 were planned to be randomized. Regorafenib was administered orally at 160 or 120 mg daily, 3 weeks on/1 week off or tamoxifen at 40 mg daily, until disease progression or development of unacceptable toxicity. The primary endpoint was Progression-Free Survival, assessed by progression according to RECIST 1.1 or death (by any cause). Secondary endpoints included Overall Survival, Best Response and CA-125 response rate. RESULTS: 68 patients were randomized. Median age was 67 years (range: 30-87). Primary site of cancer was ovarian for most patients (92.6%). Tumors were predominantly serous / (89.7%), high grade (83.6%) and initial FIGO staging was III for 69.6% of the patients. Most (79.4%) patients were included after the first line of platinum-based treatment. After a median follow-up of 32 months, there was no difference of progression-free survival (PFS) between regorafenib and tamoxifen groups (p = 0.72), with median PFS of 5.6 months (CI 90%: 3.84-7.52) for the tamoxifen arm and 4.6 months (CI 90%: 3.65-7.33) for the regorafenib arm. There was also no difference in term of overall survival, best response or CA-125 response, delay to next therapy. Regorafenib presented a less favorable safety profile than tamoxifen, with grade 3/4 events occurring for 90.9% of the patients compared to 54.3% for tamoxifen. The most frequent were cutaneous, digestive, and biological events. Notably, hand-foot syndrome occurred in 36.4% of these patients. CONCLUSION: Regorafenib presented an unfavorable toxicity profile compared to tamoxifen, with no superior efficacy in this population of patients.
引用
- Trédan O, Provansal M, Abdeddaim C, et al. Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR). Gynecol Oncol. 2021. PMID: 34696892. doi:10.1016/j.ygyno.2021.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。